<?xml version="1.0" encoding="UTF-8"?>
<p>To the best of our knowledge, no comprehensive biomarker analysis of the therapeutic effects of OX and IRI in the TR of a prospective clinical trial has been reported. Recently, retrospective molecular analyses of several prospective clinical trials on the prognosis and therapeutic effects of an anti‐EGFR antibody and bevacizumab in accordance with CMS were reported.
 <xref rid="cas14841-bib-0019" ref-type="ref">
  <sup>19</sup>
 </xref>, 
 <xref rid="cas14841-bib-0020" ref-type="ref">
  <sup>20</sup>
 </xref>, 
 <xref rid="cas14841-bib-0021" ref-type="ref">
  <sup>21</sup>
 </xref> However, there are still no clinically useful biomarkers for OX‐based and IRI‐based therapy selection, and the adverse event profile is the only factor considered in treatment selection.
</p>
